Overview

• Nineteen point seven percent of patients in the C-144-01 trial were alive at five years with no new or delayed side effects.
• Tumours shrank in 79.3 percent of participants and 5.9 percent showed no evidence of cancer after a single infusion of lifileucel.
• Lifileucel leverages a patient's tumour-infiltrating lymphocytes by isolating, expanding and reinfusing them to target melanoma cells.
• The US FDA approved lifileucel for advanced melanoma in February 2024, while UK regulators have yet to grant authorization.
• Ongoing studies are exploring lifileucel in combination with pembrolizumab to enhance response rates in advanced melanoma.